Doctors track COPD patients on common triple therapy
NCT ID NCT06422676
Summary
This study observed patients with moderate-to-severe COPD who were newly prescribed the inhaled medication BREZTRI in routine Russian clinics. Researchers tracked their symptoms, breathing ability, and treatment satisfaction over 24 weeks to see how they fared in real-world use. The goal was to understand the treatment's effectiveness and safety outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Blagoveshchensk, Russia
-
Research Site
Kazan', Russia
-
Research Site
Krasnodar, Russia
-
Research Site
Krasnoyarsk, Russia
-
Research Site
Moscow, Russia
-
Research Site
Nizhny Novgorod, Russia
-
Research Site
Novosibirsk, Russia
-
Research Site
Omsk, Russia
-
Research Site
Rostov-on-Don, Russia
-
Research Site
Ryazan, Russia
-
Research Site
Saint Petersburg, Russia
-
Research Site
Ufa, Russia
-
Research Site
Volgograd, Russia
-
Research Site
Yekaterinburg, Russia
Conditions
Explore the condition pages connected to this study.